Tekla Capital Management LLC Agios Pharmaceuticals, Inc. Transaction History

Tekla Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$33.21 - $46.54 $6.21 Million - $8.7 Million	-186,964 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$31.52 - $53.81 $928,074 - $1.58 Million	-29,444 Reduced 13.61%	186,964 $6.63 Million
Q4 2019 Feb 13, 2020	BUY	$30.08 - $50.59 $2.23 Million - $3.75 Million	74,191 Added 52.17%	216,408 $10.3 Million
Q3 2019 Nov 13, 2019	SELL	$32.4 - $49.58 $101,250 - $154,937	-3,125 Reduced 2.15%	142,217 $4.61 Million
Q2 2019 Aug 14, 2019	BUY	$46.17 - $68.1 $2.47 Million - $3.65 Million	53,566 Added 58.37%	145,342 $7.25 Million
Q1 2019 May 14, 2019	BUY	$45.92 - $67.67 $1.96 Million - $2.89 Million	42,751 Added 87.2%	91,776 $6.19 Million
Q4 2018 Feb 13, 2019	BUY	$42.73 - $76.53 $647,573 - $1.16 Million	15,155 Added 44.74%	49,025 $2.26 Million
Q3 2018 Nov 13, 2018	BUY	$71.67 - $91.95 $2.23 Million - $2.86 Million	31,060 Added 1105.34%	33,870 $2.61 Million
Q1 2018 May 14, 2018	BUY	$59.83 - $86.53 $168,122 - $243,149	2,810 New	2,810 $230,000

243

59.9M

270K

332K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $1.51B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.